Poolbeg Pharma relocates to new London headquarters at 40 Bank Street

Poolbeg Pharma

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Company has changed its registered address to 40 Bank Street, Floor 24, London, E14 5NR, United Kingdom.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Poolbeg Pharma CEO participating in key conferences in March and April 2025

Poolbeg Pharma's CEO, Jeremy Skillington, will present at major industry conferences in March and April 2025, showcasing innovative therapies and advancements.

Poolbeg Pharma granted patent in Korea for POLB 001

Poolbeg Pharma (LON:POLB) secures a crucial patent for POLB 001 in South Korea, enhancing its portfolio for treating severe influenza and other conditions.

Poolbeg Pharma granted extension to PUSU Deadline

HOOKIPA Pharma and Poolbeg Pharma enter talks for a potential acquisition aimed at developing next-generation immunotherapies for critical medical needs.

Poolbeg Pharma update on potential combination with HOOKIPA

Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations.

Poolbeg Pharma y HOOKIPA Pharma actualizan su recaudación de fondos con el apoyo de Gilead Sciences

Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos.

Poolbeg Pharma and HOOKIPA Pharma fundraise update with Gilead Sciences’ support

Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks.

Search

Search